aTyr Pharma, Inc. (NASDAQ:LIFE) Receives Average Recommendation of “Moderate Buy” from Brokerages

Shares of aTyr Pharma, Inc. (NASDAQ:LIFE – Get Rating) have been assigned a consensus recommendation of “Moderate Buy” from the six analysts that are presently covering the company, Marketbeat Ratings reports. One research analyst has rated the stock with a hold rating and five have given a buy rating to the company. The average 1-year price target among analysts that have issued a report on the stock in the last year is $19.00.

A number of brokerages recently weighed in on LIFE. Roth Mkm reaffirmed a “buy” rating and issued a $9.00 price target on shares of aTyr Pharma in a research note on Monday, March 6th. StockNews.com began coverage on shares of aTyr Pharma in a research note on Thursday. They issued a “hold” rating on the stock. Royal Bank of Canada reissued an “outperform” rating and issued a $19.00 target price on shares of aTyr Pharma in a research note on Friday, March 10th. Piper Sandler raised their price target on shares of aTyr Pharma from $9.00 to $13.00 and gave the stock an “overweight” rating in a report on Tuesday, April 11th. Finally, HC Wainwright reiterated a “buy” rating and issued a $35.00 target price on shares of aTyr Pharma in a report on Friday, March 10th.

Insider Buying and Selling at aTyr Pharma

In other news, Director Paul Schimmel acquired 200,000 shares of the firm’s stock in a transaction dated Wednesday, May 10th. The stock was acquired at an average cost of $2.25 per share, with a total value of $450,000.00. Following the transaction, the director now owns 313,023 shares in the company, valued at $704,301.75. The transaction was disclosed in a document filed with the SEC, which is available at this link. 3.14% of the stock is currently owned by corporate insiders.

Institutional Investors Weigh In On aTyr Pharma

Several institutional investors have recently modified their holdings of the company. JPMorgan Chase & Co. lifted its position in shares of aTyr Pharma by 5,093.2% during the 1st quarter. JPMorgan Chase & Co. now owns 134,868 shares of the biotechnology company’s stock worth $283,000 after purchasing an additional 132,271 shares during the last quarter. CVI Holdings LLC purchased a new stake in aTyr Pharma in the first quarter valued at $1,236,000. Samsara BioCapital LLC purchased a new stake in aTyr Pharma in the first quarter valued at $3,675,000. Squarepoint Ops LLC purchased a new stake in aTyr Pharma in the first quarter valued at $26,000. Finally, Geode Capital Management LLC lifted its position in aTyr Pharma by 139.0% in the first quarter. Geode Capital Management LLC now owns 578,902 shares of the biotechnology company’s stock valued at $1,216,000 after acquiring an additional 336,663 shares during the last quarter. 99.09% of the stock is owned by hedge funds and other institutional investors.

aTyr Pharma Price Performance

Shares of LIFE opened at $2.44 on Friday. The business’s 50-day moving average is $2.07 and its two-hundred day moving average is $2.18. The company has a debt-to-equity ratio of 0.01, a quick ratio of 8.75 and a current ratio of 8.75. aTyr Pharma has a fifty-two week low of $1.55 and a fifty-two week high of $4.28. The company has a market capitalization of $132.47 million, a P/E ratio of -1.68 and a beta of 1.21.

aTyr Pharma (NASDAQ:LIFE – Get Rating) last posted its earnings results on Thursday, March 9th. The biotechnology company reported ($0.26) earnings per share (EPS) for the quarter, topping the consensus estimate of ($0.48) by $0.22. The firm had revenue of $10.39 million for the quarter, compared to analysts’ expectations of $1.50 million. Research analysts predict that aTyr Pharma will post -1.46 earnings per share for the current year.

aTyr Pharma Company Profile

(Get Rating)

aTyr Pharma, Inc engages in the discovery and development of medicines based on novel biological pathways. Its product pipeline includes ATYR1923, ATYR2810, NRP2 mAbs, and AARS-1, DARS-1. The company was founded by Paul Schimmel, Xiang-Lei Yang and Bruce Beutler on September 8, 2005 and is headquartered in San Diego, CA.